Platinum Drug Shortage Jeopardizes Cancer Treatments Nationwide

India is facing an acute shortage of key platinum-based cancer drugs, Cisplatin and Carboplatin, critical for treating various malignancies. The scarcity, attributed to limited raw material availability, threatens patient care and prompts calls for urgent governmental intervention to ensure continuous drug supply and safeguard treatment timelines and outcomes.

Amid an escalating healthcare crisis, officials from AIIMS Delhi have sounded the alarm over a significant shortage of pivotal platinum-based cancer drugs—Cisplatin and Carboplatin. These drugs are vital in battling cancers such as head and neck, lung, ovarian, bladder, and gastrointestinal malignancies. The shortage poses a critical threat to effective cancer treatment protocols, experts warn.

The disruption has forced clinicians to resort to less effective treatment options, risking the conversion of operable cancers into non-resectable ones, an AIIMS surgical oncologist noted. There is an urgent plea for expediting domestic production and improved supply chain management at a national level to prevent further deterioration in patient outcomes.

Rajiv Singhal, General Secretary of AIOCD, highlighted a global shortfall in platinum-based raw materials as the root cause, urging government action to ensure raw material availability. Meanwhile, oncologists nationwide stress the importance of restoring normal supply channels to alleviate treatment delays and patient anxiety.